Diaceutics (LON:DXRX) Stock Price Down 3.5% – What’s Next?

Diaceutics PLC (LON:DXRX)’s stock price was down 3.5% during trading on Wednesday . The stock traded as low as GBX 137 ($1.71) and last traded at GBX 137 ($1.71). Approximately 168,225 shares changed hands during trading, an increase of 3% from the average daily volume of 163,573 shares. The stock had previously closed at GBX 142 ($1.77).

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on DXRX shares. Canaccord Genuity Group restated a “buy” rating and set a GBX 160 ($1.99) target price on shares of Diaceutics in a report on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 160 ($1.99) price objective on shares of Diaceutics in a research note on Tuesday, December 17th.

Diaceutics Price Performance

The firm has a market cap of £115.72 million, a price-to-earnings ratio of -4,566.67 and a beta of 0.58. The business’s 50-day moving average price is GBX 129.12 and its two-hundred day moving average price is GBX 128.49. The company has a debt-to-equity ratio of 2.93, a current ratio of 4.85 and a quick ratio of 9.92.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.